IP Library Granted Patent US 10,413,621
Granted Patent B2
US 10,413,621 · App. 13/502,852 · Granted Sep 17, 2019

Composition and methods for imaging cells

Inventors: James Basilion (Shaker Heights, OH); Kirti Dhingra (Cleveland, OH); Thomas J. Meade (Evanston, IL); Sarah Grace Kamper (Evanston, IL)
Assignee: CASE WESTERN RESERVE UNIVERSITY
A61K49/085G01N33/569G01N2800/52
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,413,621
App. No.
13/502,852
Granted
Sep 17, 2019
Kind
B2
Abstract

A composition for imaging a cell includes a first imaging probe and a second imaging probe that include respectively a first reporter moiety and a second reporter moiety. The first reporter moiety and the second reporter moiety form a signaling complex that produces a detectable signal when the first imaging probe and second imaging probe complex with first and second biomarkers of the cell.

Claims (14)

1. A composition for imaging a cell having a first biomarker and a second biomarker that is different than the first biomarker, the composition comprising:

a first imaging probe comprising a first targeting moiety that is linked to a self-immolative enzyme-activated magnetic resonance contrast agent conjugated to a biotin attachment molecule via a streptavidin linkage;

wherein O represents a coordinate metal ion and is selected from the group consisting of Gd(III), Fe(III), Mn(III), Y(III), Cr(III), Eu(III), Tb(III), and Dy(III), and X is an optional aliphatic and/or aromatic group; and

a second imaging probe comprising a second targeting moiety that is linked to an enzyme molecule or fragments thereof via a linker region, the second targeting moiety being different than the first targeting moiety and specifically complexing with the second biomarker;

wherein the self-immolative enzyme-activated magnetic resonance contrast agent of the first imaging probe and the enzyme or fragments thereof of the second imaging probe form a signaling complex that produces a detectable signal when the first imaging probe and second imaging probe complex with first and second biomarkers of the cell.

2. The composition of claim 1 , wherein the enzyme is β-galactosidase.

3. The composition of claim 1 , wherein at least one of the first and second biomarkers is extracellular.

4. The composition of claim 1 , wherein at least one of the first and second biomarkers is intracellular.

5. The composition of claim 1 , wherein at least one of the first and second biomarkers is selected from the group consisting of a cellular protease, a kinase, a protein, a cell surface receptor, fatty acid, and lipid.

6. The composition of claim 1 , wherein the first and second biomarkers are cancer cell surface receptors.

7. The composition of claim 1 , wherein the first and second targeting moieties is selected from the group consisting of polypeptides, polynucleotides, lipids, receptor molecules, ligand molecules, aptamers, peptidomimetics, elemental compounds, antibodies, and antibody fragments.

8. The composition of claim 1 , wherein the linker region of the second imaging probe comprises a polymer.

9. The composition of claim 1 , wherein the linker region of the second imaging probe comprises at least one peptide linker.

10. The composition of claim 9 , wherein the at least one peptide linker comprises a biotin-streptavidin-biotin linkage.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 18, 2015
From: BASILION, JAMES
To: CASE WESTERN RESERVE UNIVERSITY
Reel/Frame 037071/0991 →
Continuity (2)
Provisional Application 61252882 · Oct 19, 2009
Related Publication 20120207684A1 · Aug 16, 2012
Cited By (2)
US 12,207,925 US 12,691,185